Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Study ID: NCT00656812
Phase: PHASE2
Status: Completed

Conditions

Lymphoma of Mucosa-Associated Lymphoid Tissue

Eligibility Criteria

Sex: ALL
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Rituximab — DRUG
375 mg/m2 on day 1 of a 21-day treatment cycle
2-CdA — DRUG
0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle

Study Details

The purpose of this trial is to evaluate whether a Rituximab plus 2 CdA combination therapy is effective and safe in the treatment of patients with advanced or relapsed lymphoma of the mucosa associated lymphoid tissue (MALT).

Key Dates

Start date: May 31, 2008
Status verified: Dec 2013
Primary completion: Sep 30, 2011
Completion: Sep 30, 2011

Study Design

Enrollment: 40 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: Treatment Arm
Combination therapy Rituximab plus 2CdA

Primary Outcome Measure

Response rate [ Time Frame: After 2, 4 and 6 cycles of therapy ]